BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

BACKGROUND: Germline mutations of the BRCA tumour suppressors have been associated with increased risk of pancreatic cancer. Clinical evidence suggests that these patients may be more sensitive to treatment with cisplatin. As the frequency of germline BRCA mutations is low, definitive experimental d...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Translational Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522629/
https://ncbi.nlm.nih.gov/pubmed/26180923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.220
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items